$0.42
(Market cap
$13,403 Mln
Recently Viewed
Clear AllMarket cap
$13,403 Mln
Revenue (TTM)
$2,861 Mln
P/E Ratio
28.5
P/B Ratio
4.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$479 Mln
ROE
0.2 %
ROCE
14.3 %
Industry P/E
--
EV/EBITDA
18.5
Debt to Equity
0.1
Book Value
$31.7
EPS
$4.7
Face value
--
Shares outstanding
100,581,991
CFO
$1,182.07 Mln
EBITDA
$1,030.77 Mln
Net Profit
$526.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
| -7.2 | 3.1 | -4.2 | 29.4 | 8.1 | 6.4 | 10.5 |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100
| 1.4 | 10.1 | 2.5 | 37.7 | 22.9 | 13.3 | 14.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
| 3.9 | 3.6 | 10.3 | 40.2 | -11.1 | -10.8 | 50.5 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
|
131.6 | 13,402.6 | 2,860.5 | 478.6 | 24.1 | 16.4 | 28.5 | 4.1 |
| 314.1 | 41,317.3 | 3,713.9 | 313.8 | 11.2 | 73.3 | 133.5 | 52.4 | |
| 143.1 | 31,186.3 | 606.4 | -1,276.8 | -196.7 | -249.3 | -- | 42.2 | |
| 74.7 | 12,506.7 | 944.0 | -381.0 | -31.6 | -70.7 | -- | 25.6 | |
| 159.9 | 29,945.3 | 16,310.0 | 1,360.0 | 14.2 | 21.6 | 21.9 | 4.4 | |
| 54.5 | 21,304.7 | 1,944.0 | -2,822.0 | -142.4 | -28.9 | -- | 2.5 | |
| 763.8 | 79,350.1 | 14,342.9 | 4,504.9 | 36.8 | 14.9 | 18.1 | 2.5 | |
| 23.4 | 19,500.6 | 0.0 | -1,079.6 | -- | -206.1 | -- | 29.6 | |
| 572.8 | 25,787.3 | 3,182.7 | 1,334.7 | 54.1 | 19.7 | 21.1 | 3.6 | |
| 439.4 | 112,223.5 | 12,074.6 | 3,953.2 | 38.4 | 22.5 | 28.8 | 5.9 |
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive... dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. Read more
CEO & Director
Dr. Kevin C. Gorman Ph.D.
CEO & Director
Mr. Kyle W. Gano Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Neurocrine Biosciences Inc (NBIX) is $131.60 (NASDAQ) as of 23-Apr-2026 12:37 EDT. Neurocrine Biosciences Inc (NBIX) has given a return of 8.1% in the last 3 years.
The P/E ratio of Neurocrine Biosciences Inc (NBIX) is 28.47 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
30.38
|
4.47
|
|
2024
|
41.15
|
5.42
|
|
2023
|
53.98
|
6.04
|
|
2022
|
77.93
|
7.05
|
|
2021
|
90.21
|
5.88
|
The 52-week high and low of Neurocrine Biosciences Inc (NBIX) are Rs 160.18 and Rs 101.15 as of 23-Apr-2026.
Neurocrine Biosciences Inc (NBIX) has a market capitalisation of $ 13,403 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Neurocrine Biosciences Inc (NBIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.